2016 AIChE Annual Meeting
(484i) Fe3O4 Incorporated Metal Organic Framework MIL-100(Fe) As a Drug Carrier
Authors
Fe3O4
promoted metal organic framework MIL-100(Fe): Can be a promising candidate as a
drug carrier
Abhik Bhattacharjee and Sasidhar Gumma
Department of Chemical Engineering, Indian Institute
of Technology Guwahati
Email: s.gumma@iitg.ernet.in
In this study, porous metal
organic framework (MOF) MIL-100(Fe) and magnetic nanoparticle MOF composites
i.e. Fe3O4@MIL-100 were investigated as drug delivery
vehicles for anticancer drug doxorubicin hydrochloride. Magnetite
is an inorganic metal oxide was chosen for its nontoxicity and high magnetic
saturation. MIL-100 (Fe) was synthesized by solvothermal route at about 150 °C from
its organic linker like trimesic acid (BTC). Magnetite were synthesized
according to standard procedures in literature to yield magnetic nanoparticles
(MNPs) of about 10-30 nm. A series of MNP and MOF composites i.e. Fe3O4@MIL-100(Fe)
were prepared by adding magnetite in different molar ratio in the raw precursor
of MIL-100 at temperature of 150 °C. All porous adsorbent samples were characterized
by X-ray diffraction, Nitrogen adsorption-desorption isotherm and Transmission
electron microscopy (TEM) methods. Doxorubicin hydrochloride (DOX), a well-known
anticancer drug for the treatment of various cancer syndromes like leukaemia,
lymphoma, and carcinoma was chosen as a model drug for current study. The drug was
loaded on to the MOF composite by equilibrating the aqueous DOX solution with
the porous MNP incorporated MOFs. For release study, DOX loaded carriers,
were dispersed in simulated phosphate-buffered saline (PBS) solution at a pH of
7.4 and incubated in a shaker at 37 °C in the dark. The sample was centrifuged
and the supernatants were collected for analysis at periodic time intervals. A
fresh PBS which is equal in volume to that of the sample withdrawn for analysis
is added to the contents of the incubation flask. The results indicate that the
drug loading capacities of the Fe3O4@MIL-100 for the
composites studied in this work are higher than both pure Fe3O4
and pure MIL-100. The release kinetics also indicate sustained and stable
release of DOX for more than ten days by incorporating MNPs into MOF
structure.
Table
1: Molar compositions and drug loading capacities of different carriers
Drug carriers |
Molar ratio Fe:BTC:Fe3O4 |
DOX Loading (wt%)
|
Fe3O4 |
0:0:1 |
11.37 |
MIL-100 |
50:33:0 |
11.09 |
Fe3O4(50)@MIL-100 |
50:33:1 |
18.31 |
Fe3O4(100)@MIL-100 |
50:33:2 |
18.45 |
Fe3O4(125)@MIL-100 |
50:33:2.5 |
19.69 |
Fe3O4(150)@MIL-100 |
50:33:3 |
19.00 |
Fe3O4(200)@MIL-100 |
50:33:4 |
15.14 |
Fe3O4(400)@MIL-100 |
50:33:9 |
13.81 |
Fig. 1: TEM micrograph
of Fe3O4@MIL-100 and DOX release study on different carriers
References:
1.
R. Massart, IEEE Trans.Magn., (1981), 17,1247.
2.
P. Horcajada et.al. Nature, (2010), 9, 172.